Skip to main content
Erschienen in: Heart Failure Reviews 4-5/2012

01.09.2012

Pharmacotherapy of heart failure in the elderly: adverse events

verfasst von: Michael W. Rich

Erschienen in: Heart Failure Reviews | Ausgabe 4-5/2012

Einloggen, um Zugang zu erhalten

Abstract

Aging is associated with numerous alterations in body composition and organ function that result in substantial changes in the absorption, distribution, metabolism, and elimination of virtually all drugs. In addition, older patients with heart failure (HF) almost invariably have multiple coexisting medical conditions for which they are receiving medications. This article reviews common adverse drug effects and drug interactions associated with HF therapy in older patients and discusses strategies for reducing the risk of adverse drug events. In order to minimize these risks, it is essential that clinicians avoid prescribing unnecessary medications, adjust medication dosages to optimally balance benefits and side effects, and remain ever vigilant to the potential for medications to cause or contribute to clinically important adverse events and impaired quality of life. In treating older HF patients, the oft-cited dictum “start low, go slow” clearly applies. Despite the inherent challenges, with careful management and close follow-up, most older HF patients can be successfully treated through the judicious use of guideline-recommended HF therapies.
Literatur
1.
Zurück zum Zitat Stegemann S, Ecker F, Maio M et al (2010) Geriatric drug therapy: neglecting the inevitable majority. Ageing Res Rev 9:384–398PubMedCrossRef Stegemann S, Ecker F, Maio M et al (2010) Geriatric drug therapy: neglecting the inevitable majority. Ageing Res Rev 9:384–398PubMedCrossRef
2.
Zurück zum Zitat Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67–76PubMedCrossRef Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67–76PubMedCrossRef
3.
Zurück zum Zitat Braunstein JB, Anderson GF, Gerstenblith G et al (2003) Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 42:1226–1233PubMedCrossRef Braunstein JB, Anderson GF, Gerstenblith G et al (2003) Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 42:1226–1233PubMedCrossRef
4.
Zurück zum Zitat Rich MW (2005) Heart failure in the oldest patients: the impact of comorbid conditions. Am J Geriatr Card 14:134–141CrossRef Rich MW (2005) Heart failure in the oldest patients: the impact of comorbid conditions. Am J Geriatr Card 14:134–141CrossRef
5.
Zurück zum Zitat Stevens LA, Levey AS (2005) Chronic kidney disease in the elderly—how to assess risk. N Engl J Med 352:2122–2124PubMedCrossRef Stevens LA, Levey AS (2005) Chronic kidney disease in the elderly—how to assess risk. N Engl J Med 352:2122–2124PubMedCrossRef
6.
Zurück zum Zitat Hanlon JT, Aspinall SL, Semla TP et al (2009) Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc 57:335–340PubMedCrossRef Hanlon JT, Aspinall SL, Semla TP et al (2009) Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc 57:335–340PubMedCrossRef
7.
Zurück zum Zitat Zhou XJ, Rakheja D, Yu X, Saxena R, Vaziri ND, Silva FG (2008) The aging kidney. Kidney Internat 74(6):710–720CrossRef Zhou XJ, Rakheja D, Yu X, Saxena R, Vaziri ND, Silva FG (2008) The aging kidney. Kidney Internat 74(6):710–720CrossRef
8.
Zurück zum Zitat Kenney WL, Chiu P (2001) Influence of age on thirst and fluid intake. Med Sci Sports Exerc 33:1524–1532PubMedCrossRef Kenney WL, Chiu P (2001) Influence of age on thirst and fluid intake. Med Sci Sports Exerc 33:1524–1532PubMedCrossRef
9.
Zurück zum Zitat Shem S (1979) House of God. Random House, Inc, New York Shem S (1979) House of God. Random House, Inc, New York
10.
Zurück zum Zitat Steinman MA, Hanlon JT (2010) Managing medications in clinically complex elders. “There’s got to be a happy medium”. JAMA 304:1592–1601PubMedCrossRef Steinman MA, Hanlon JT (2010) Managing medications in clinically complex elders. “There’s got to be a happy medium”. JAMA 304:1592–1601PubMedCrossRef
11.
Zurück zum Zitat Pitt B, Segal R, Martinez FA et al (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747–752PubMedCrossRef Pitt B, Segal R, Martinez FA et al (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747–752PubMedCrossRef
12.
Zurück zum Zitat Pitt B, Poole-Wilson PA, Segal R et al (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–1587PubMedCrossRef Pitt B, Poole-Wilson PA, Segal R et al (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–1587PubMedCrossRef
13.
Zurück zum Zitat Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef
14.
Zurück zum Zitat Levey AS, Bosch JP, Lewis JB (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new predication equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMed Levey AS, Bosch JP, Lewis JB (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new predication equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMed
15.
Zurück zum Zitat Massie BM, Armtrong PW, Cleland JG et al (2001) Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med 161:165–171PubMedCrossRef Massie BM, Armtrong PW, Cleland JG et al (2001) Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med 161:165–171PubMedCrossRef
16.
Zurück zum Zitat Packer M, Poole-Wilson PA, Armstrong PW et al (1999) Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100:2312–2318PubMed Packer M, Poole-Wilson PA, Armstrong PW et al (1999) Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100:2312–2318PubMed
17.
Zurück zum Zitat Juurlink DN, Mamdani MM, Lee DS et al (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:543–551PubMedCrossRef Juurlink DN, Mamdani MM, Lee DS et al (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:543–551PubMedCrossRef
18.
Zurück zum Zitat Tamirisa KP, Aaronson KD, Koelling TM (2004) Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 148:971–978PubMedCrossRef Tamirisa KP, Aaronson KD, Koelling TM (2004) Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 148:971–978PubMedCrossRef
19.
20.
Zurück zum Zitat Hunt SA, Abraham WT, Chin MH et al (2009) 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. Circulation 119:e391–e479PubMedCrossRef Hunt SA, Abraham WT, Chin MH et al (2009) 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. Circulation 119:e391–e479PubMedCrossRef
21.
Zurück zum Zitat Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation 107:346–354PubMedCrossRef Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation 107:346–354PubMedCrossRef
22.
Zurück zum Zitat Lakatta EG (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 107:490–497PubMedCrossRef Lakatta EG (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 107:490–497PubMedCrossRef
23.
Zurück zum Zitat Hanratty CG, McGlinchey P, Johnston GD, Passmore AP (2000) Differential pharmacokinetics of digoxin in elderly patients. Drugs Ageing 17:353–362CrossRef Hanratty CG, McGlinchey P, Johnston GD, Passmore AP (2000) Differential pharmacokinetics of digoxin in elderly patients. Drugs Ageing 17:353–362CrossRef
24.
Zurück zum Zitat Ahmed A, Rich MW, Love TE et al (2006) Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27:178–186PubMedCrossRef Ahmed A, Rich MW, Love TE et al (2006) Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27:178–186PubMedCrossRef
25.
Zurück zum Zitat Rich MW, McSherry F, Williford WO, Yusuf S (2001) Digitalis Investigation Group. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 38:806–813PubMedCrossRef Rich MW, McSherry F, Williford WO, Yusuf S (2001) Digitalis Investigation Group. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 38:806–813PubMedCrossRef
26.
Zurück zum Zitat Weil J, Sen Gupta R, Herfarth H (2004) Nonocclusive mesenteric ischemia induced by digitalis. Int J Colorectal Dis 19:277–280PubMedCrossRef Weil J, Sen Gupta R, Herfarth H (2004) Nonocclusive mesenteric ischemia induced by digitalis. Int J Colorectal Dis 19:277–280PubMedCrossRef
27.
Zurück zum Zitat Schaefer DC, Cheskin LJ (1998) Constipation in the elderly. Am Fam Phys 58:907–914 Schaefer DC, Cheskin LJ (1998) Constipation in the elderly. Am Fam Phys 58:907–914
28.
Zurück zum Zitat Kitzman DW, Gardin JM, Gottdiener JS et al (2001) Importance of heart failure with preserved systolic function in patients ≥65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 87:413–419PubMedCrossRef Kitzman DW, Gardin JM, Gottdiener JS et al (2001) Importance of heart failure with preserved systolic function in patients ≥65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 87:413–419PubMedCrossRef
29.
Zurück zum Zitat Heart Failure Society of America (2010) Comprehensive heart failure practice guidelines. Heart failure in patients with preserved ejection fraction. J Cardiac Fail 16:e73–e97CrossRef Heart Failure Society of America (2010) Comprehensive heart failure practice guidelines. Heart failure in patients with preserved ejection fraction. J Cardiac Fail 16:e73–e97CrossRef
30.
Zurück zum Zitat Tsang TS, Gersh BJ, Appleton CP et al (2002) Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 40:1636–1644PubMedCrossRef Tsang TS, Gersh BJ, Appleton CP et al (2002) Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 40:1636–1644PubMedCrossRef
31.
Zurück zum Zitat Seymour RM, Routledge PA (1998) Important drug–drug interactions in the elderly. Drugs Ageing 12:485–494CrossRef Seymour RM, Routledge PA (1998) Important drug–drug interactions in the elderly. Drugs Ageing 12:485–494CrossRef
32.
Zurück zum Zitat Whelton A (1999) Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 106:13S–24SPubMedCrossRef Whelton A (1999) Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 106:13S–24SPubMedCrossRef
33.
Zurück zum Zitat Page J, Henry D (2000) Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Int Med 160:777–784CrossRef Page J, Henry D (2000) Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Int Med 160:777–784CrossRef
34.
Zurück zum Zitat Vassallo P, Trohman RG (2007) Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 298:1312–1322PubMedCrossRef Vassallo P, Trohman RG (2007) Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 298:1312–1322PubMedCrossRef
35.
Zurück zum Zitat Shirolkar SC, Fiuzat M, Becker RC (2010) Dronedarone and vitamin K antagonists: a review of drug–drug interactions. Am Heart J 160:577–582PubMedCrossRef Shirolkar SC, Fiuzat M, Becker RC (2010) Dronedarone and vitamin K antagonists: a review of drug–drug interactions. Am Heart J 160:577–582PubMedCrossRef
36.
Zurück zum Zitat Obialo CI, Ofili EO, Mirza T (2002) Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol 90:663–665PubMedCrossRef Obialo CI, Ofili EO, Mirza T (2002) Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol 90:663–665PubMedCrossRef
37.
Zurück zum Zitat Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST (2008) Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 300:2867–2878PubMedCrossRef Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST (2008) Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 300:2867–2878PubMedCrossRef
38.
Zurück zum Zitat Cohen PA, Ernst E (2010) Safety of herbal supplements: a guide for cardiologists. Cardiovasc Therapeut 28:246–253CrossRef Cohen PA, Ernst E (2010) Safety of herbal supplements: a guide for cardiologists. Cardiovasc Therapeut 28:246–253CrossRef
39.
Zurück zum Zitat Gastelurrutia P, Benrimoj SI, Espejo J, Tuneu L, Mangues MA, Bayes-Genis A (2011) Negative clinical outcomes associated with drug-related problems in heart failure (HF) outpatients: impact of a pharmacist in a multidisciplinary HF clinic. J Cardiac Fail 17:217–223CrossRef Gastelurrutia P, Benrimoj SI, Espejo J, Tuneu L, Mangues MA, Bayes-Genis A (2011) Negative clinical outcomes associated with drug-related problems in heart failure (HF) outpatients: impact of a pharmacist in a multidisciplinary HF clinic. J Cardiac Fail 17:217–223CrossRef
40.
Zurück zum Zitat Fulmer TT, Feldman PH, Kim TS et al (1999) An intervention study to enhance medication compliance in community-dwelling elderly individuals. J Gerontol Nursing 25:6–14 Fulmer TT, Feldman PH, Kim TS et al (1999) An intervention study to enhance medication compliance in community-dwelling elderly individuals. J Gerontol Nursing 25:6–14
41.
Zurück zum Zitat Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part 1: aging arteries: a “set up” for vascular disease. Circulation 107:139–146PubMedCrossRef Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part 1: aging arteries: a “set up” for vascular disease. Circulation 107:139–146PubMedCrossRef
42.
Zurück zum Zitat Gupta V, Lipsitz LA (2007) Orthostatic hypotension in the elderly: diagnosis and treatment. Am J Med 120:841–847PubMedCrossRef Gupta V, Lipsitz LA (2007) Orthostatic hypotension in the elderly: diagnosis and treatment. Am J Med 120:841–847PubMedCrossRef
43.
Zurück zum Zitat Poluri A, Mores J, Cook DB, Findley TW, Cristian A (2005) Fatigue in the elderly population. Phys Med Rehab Clin North Am 16:91–108CrossRef Poluri A, Mores J, Cook DB, Findley TW, Cristian A (2005) Fatigue in the elderly population. Phys Med Rehab Clin North Am 16:91–108CrossRef
44.
45.
Zurück zum Zitat Choi JY, Morris JC, Hsu CY (1998) Aging and cerebrovascular disease. Neurol Clin 16:687–711PubMedCrossRef Choi JY, Morris JC, Hsu CY (1998) Aging and cerebrovascular disease. Neurol Clin 16:687–711PubMedCrossRef
46.
Zurück zum Zitat Cherubini A, Lowenthal DT, Paran E, Mecocci P, Williams LS, Senin U (2007) Hypertension and cognitive function in the elderly. Am J Therapeut 14:533–554CrossRef Cherubini A, Lowenthal DT, Paran E, Mecocci P, Williams LS, Senin U (2007) Hypertension and cognitive function in the elderly. Am J Therapeut 14:533–554CrossRef
Metadaten
Titel
Pharmacotherapy of heart failure in the elderly: adverse events
verfasst von
Michael W. Rich
Publikationsdatum
01.09.2012
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 4-5/2012
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-011-9263-1

Weitere Artikel der Ausgabe 4-5/2012

Heart Failure Reviews 4-5/2012 Zur Ausgabe

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.